Blog
RSS FeedPosted by Michael Wonder on 10 Sep 2020
Terns Pharmaceuticals receives fast track designation for TERN-201 as a treatment for NASH
10 September 2020 - Clinical trial of semicarbazide-sensitive amine oxidase inhibitor TERN-201 in NASH patients planned for early 2021. ...
Posted by Michael Wonder on 10 Sep 2020
China debates cutting US access to drugs as hostilities spike
10 September 2020 - Some government advisers say China should cut drug exports to the US if Washington increases sanctions. ...
Posted by Michael Wonder on 10 Sep 2020
PHARMAC seeking views on widened access to juvenile idiopathic arthritis medicines
11 September 2020 - PHARMAC is looking at widening access to three funded treatments – adalimumab, etanercept and tocilizumab – to ...
Posted by Michael Wonder on 10 Sep 2020
COVID-19 drug rationed in the US is plentiful in developing countries
9 September 2020 - During the coronavirus surge in Texas this summer, Dr. Thomas Patterson said he only had enough ...
Posted by Michael Wonder on 10 Sep 2020
‘Hell has frozen over’: The pharmaceutical industry stands in for a politically impaired FDA
10 September 2020 - How can Americans tell when the FDA has become so politically impaired that it cannot serve ...
Posted by Michael Wonder on 10 Sep 2020
Halozyme announces Janssen submission for FDA approval of Darzalex Faspro (daratumumab and hyaluronidase-fihj) for the treatment of patients with light chain amyloidosis
10 September 2020 - Follows FDA approval of Darzalex Faspro utilising Enhanze technology in May 2020 for the treatment of patients ...
Posted by Michael Wonder on 10 Sep 2020
Lilly commits Insulin Value Program, featuring $35 copay card, to suite of affordability solutions for people with diabetes
10 September 2020 - People with commercial insurance and the uninsured can access the copay card by calling the Lilly Diabetes ...
Posted by Michael Wonder on 10 Sep 2020
FDA approves Trelegy Ellipta as the first once daily single inhaler triple therapy for the treatment of both asthma and COPD in the US
9 September 2020 - New asthma indication for Trelegy Ellipta introduces an important option for patients to the current treatment ...
Posted by Michael Wonder on 10 Sep 2020
BeiGene announces acceptance and priority review by Health Canada of new drug submission for Brukinsa (zanubrutinib) in Waldenström’s macroglobulinaemia
9 September 2020 - BeiGene today announced that its new drug submission for Brukinsa (zanubrutinib) for the treatment of patients with ...
Posted by Michael Wonder on 10 Sep 2020
Active ingredient prescribing
10 September 2020 - Active Ingredient Prescribing will ensure consumers receive consistent and standardised medicines information. ...
Posted by Michael Wonder on 09 Sep 2020
Scottish Medicines Consortium accepts nasal spray for depression previously rejected by NICE
8 September 2020 - Esketamine nasal spray can now be provided on the NHS in Scotland for adults with major depressive ...
Posted by Michael Wonder on 09 Sep 2020
CANbridge Pharmaceuticals receives Chinese marketing approval for Hunterase first enzyme replacement therapy for Hunter syndrome in China
9 September 2020 - CANbridge Pharmaceuticals announced that it received marketing approval from China’s National Medical Products Administration for Hunterase (idursulfase ...
Posted by Michael Wonder on 09 Sep 2020
New diabetes drug funding format is “unethical”
10 September 2020 - An organisation which has campaigned to change the drugs used in New Zealand to treat type ...
Posted by Michael Wonder on 09 Sep 2020
What does it take for a HTA agency to accept a claim of clinical superiority?
10 September 2020 - The recently published PBAC Public Summary Document for AbbVie’s JAK inhibitor Rinvoq reveals a very interesting development. ...
Posted by Michael Wonder on 09 Sep 2020
Evaluation of precision medicine assessment reports of the Belgian health care payer to inform reimbursement decisions
7 September 2020 - Precision medicines rely on companion diagnostics to identify patient subgroups eligible for receiving the pharmaceutical product. ...